Candel Therapeutics (CADL) Stock Forecast & Price Target

Candel Therapeutics is currently in the final stretch towards their planned 4Q26 BLA filing for their lead product, aglatimagene. This milestone, supported by favorable data from Phase 3 trials and strong interest from payers, could bring significant value to the company. However, investors should be aware of Candel's need for additional capital in the future and potential risks associated with patient enrollment in their multiple clinical trials.

Candel Therapeutics is in the clinical trial stage with its off-the-shelf viral immunotherapies for cancer treatment, and although the company reported positive data and received IND clearance for a Phase 2 study, there is uncertainty around the timing and design of the study. The company's ability to raise funds may also be limited if clinical data are negative or if FDA approval is delayed or rejected. While there is potential for CAN-2409 to have a positive impact on metastasis and survival in NSCLC, the efficacy and placement of additional injections require confirmation. Additionally, the potential for movement into earlier treatment settings depends on the success of Phase 3 results. These factors contribute to a negative outlook on the stock.